S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes.
Cindy LinLaura Garcia-GeriqueErin E BonnerJerome MastioMatthew RosenwasserZachary CruzMichael E LawlerLuca BernabeiKar MuthumaniJingjing LiuMortimer PonczThomas VoglMarie TörngrenHelena ErikssonDan T VoglDmitry I GabrilovichYulia NefedovaPublished in: Cancer research communications (2023)
We identified a novel mechanism by which myeloid cells promote myeloma progression independently of the adaptive immune system. Specifically, we discovered a novel role of S100A8/S100A9, the most abundant proteins produced by neutrophils and monocytes, in regulation of myeloma progression via promotion of the megakaryocyte expansion and angiogenesis. Tasquinimod, an inhibitor of S100A9, has potent antimyeloma effects as a single agent and in combination with lenalidomide and with proteasome inhibitors.